Moderna Stock Price and Forecast: MRNA may fall to $188 or $157

Moderna in continuation pattern.
Moderna stock has been hammered in November.
MRNA shares are down nearly 30% this month.

Ivan Brian FXStreet

Moderna (MRNA) stock rallied just over 3% on Wednesday in a continuation of recent small gains seen after the tumultuous hammering the stock has suffered this month. Moderna shares are down 27% over the last month despite recovering somewhat this week, up 6% now. Moderna is still snapping back after stretching too far during the pandemic. The pace of earnings growth has slowed despite the company exploding due to the coronavirus pandemic. Vaccine uptake has likely peaked, and revenue growth slowing will see a reevaluation of the underlying share price. This is what is currently happening.

Moderna (MRNA) stock news

While many are arguing the development of antiviral pills is what is hurting Moderna's share price the most, we actually feel it was the weak earnings report. This highlighted a few things. Number one: Moderna is way too reliant on one stream of revenue, that of a covid vaccine. It does have numerous other candidates in trial stages, but only a few have reached phase-3 trials. It takes years for treatments to go through stage trials. Covid did see this process speed up, but it will be back to multiple-year development timelines from now on. What the earnings highlighted the most was a revenue growth slowdown. Once that showed up, it was inevitable that investors would reassess and rebalance their Moderna holdings.

Just in case you are not aware, other headwinds exist. These include the development of antiviral treatments for covid by both Pfizer (PFE) and Merck (MRK) to continuing haggles, which may turn legal, between Moderna and the US government over intellectual property rights for the development of Moderna's covid vaccine.

Moderna (MRNA) stock forecast

The move remains in our view a consolidation of recent losses. A consolidation means a continuation phase is likely, and so a break lower is the most probable outcome. Only breaking the strong resistance from $255 to $265 will change our view. This is the 200-day moving average and the yearly volume-weighted average price (VWAP), so it is a strong resistance to break above. Instead, we are looking for a break lower to $188.41 and then $157, where it will be time to reevalaute the argument.

MRNA 1-day chart

Premium

You have reached your limit of 3 free articles for this month.

Start your subscription and get access to all our original articles.

Subscribe to Premium Sign In

Author

Ivan Brian

FXStreet

Ivan Brian started his career with AIB Bank in corporate finance and then worked for seven years at Baxter. He started as a macro analyst before becoming Head of Research and then CFO.

AUD/USD eyes 0.7150 barrier nine-day EMA

AUD/USD inches higher after registering modest losses in the previous day, trading around 0.7130 during the Asian hours. The technical analysis of the daily chart indicates that the pair is moving sideways within the rectangle pattern, suggesting a consolidation as neither the bulls nor the bears have enough momentum to take control of the market.

USD/JPY trades below 160.00 intervention threshold; bullish bias intact

The USD/JPY pair attracts some sellers during the Asian session amid fears that authorities will step in again to prop up the Japanese Yen. Furthermore, the Israel-Lebanon truce prompts some profit-taking around the US Dollar and exerts downward pressure on the currency pair.

Gold meets contention near $4,420…for now

Gold extends its recovery past the $4,500 mark per troy ounce on Thursday. The yellow metal’s advance comes amid the resurgence of some selling interest around the, improving risk sentiment, and declining US Treasury yields across the curve.

Bitcoin’s massive storm is back: Why the sell-off is far from over

Bitcoin price action over the last few weeks has felt less like a normal, healthy correction and more like a slow grinding crash that continues to wreak havoc on holdings and trading accounts. And everything suggests that the dramatic crash isn’t over.

Nonfarm payrolls: Testing the limits of Fed policy patience

The upcoming nonfarm payrolls report for May will provide the final update on the US labor market before Kevin Warsh attends his first policy meeting as the new Fed Chair later this month.

Recession on paper: What really moves the Canadian Loonie now?

Statistics Canada handed the headline writers a gift and the analysts a headache. Real GDP shrank 0.1% on an annualized basis in the first quarter, and with the fourth quarter of 2025 revised down to a 1.0% contraction, that is two negative quarters in a row, the textbook definition of a technical recession and Canada's first since the pandemic.